MX2021015711A - Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares. - Google Patents

Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares.

Info

Publication number
MX2021015711A
MX2021015711A MX2021015711A MX2021015711A MX2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A
Authority
MX
Mexico
Prior art keywords
prevotella
histicola
melaninogenica
copd
pulmonary disease
Prior art date
Application number
MX2021015711A
Other languages
English (en)
Inventor
Veena Taneja
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2021015711A publication Critical patent/MX2021015711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Este documento proporciona métodos y materiales relacionados con el tratamiento de una afección pulmonar, tal como enfermedad pulmonar obstructiva crónica (EPOC), utilizando una composición que contiene Prevotella viva (por ejemplo, P. histicola y/o P. melaninogenica), Prevotella aniquilada (o muerta) (por ejemplo, P. histicola y/o P. melaninogenica), componentes de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), vesículas (por ejemplo, OMV) de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), o una combinación de las mismas. Por ejemplo, se proporcionan métodos y materiales para usar una composición que contiene Prevotella viva (por ejemplo, P. histicola y/o P. melaninogenica), Prevotella aniquilada (o muerta) (por ejemplo, P. histicola y/o P. melaninogenica), componentes de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), vesículas (por ejemplo, OMV) de Prevotella (por ejemplo, P. histicola y/o P. melaninogenica), o una combinación de las mismas para tratar una afección pulmonar, tal como EPOC.
MX2021015711A 2019-06-17 2020-06-17 Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares. MX2021015711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862186P 2019-06-17 2019-06-17
PCT/US2020/038084 WO2020257248A1 (en) 2019-06-17 2020-06-17 Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions

Publications (1)

Publication Number Publication Date
MX2021015711A true MX2021015711A (es) 2022-02-03

Family

ID=74037580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015711A MX2021015711A (es) 2019-06-17 2020-06-17 Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares.

Country Status (11)

Country Link
US (1) US20220296657A1 (es)
EP (1) EP3983067A4 (es)
JP (1) JP2022537178A (es)
KR (1) KR20220024466A (es)
CN (1) CN114340732A (es)
AU (1) AU2020295393A1 (es)
BR (1) BR112021025416A2 (es)
CA (1) CA3143597A1 (es)
CO (1) CO2022000029A2 (es)
MX (1) MX2021015711A (es)
WO (1) WO2020257248A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses
US20240148797A1 (en) * 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2024097250A1 (en) * 2022-10-31 2024-05-10 The Trustees Of Columbia University In The City Of New York Polymeric carrier for probiotics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) * 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
CN102755646A (zh) * 2002-07-19 2012-10-31 艾博特生物技术有限公司 TNF α相关疾病的治疗
EP3679798B1 (en) * 2015-02-03 2021-11-17 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating arthritis
KR20180056419A (ko) * 2015-09-09 2018-05-28 레비비코르 인코포레이션 이종 장기이식을 위한 멀티-형질전환 피그
BR112020004347A2 (pt) * 2017-09-08 2020-09-08 Evelo Biosciences, Inc. vesículas extracelulares de prevotella
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses

Also Published As

Publication number Publication date
CN114340732A (zh) 2022-04-12
EP3983067A4 (en) 2023-06-14
KR20220024466A (ko) 2022-03-03
CO2022000029A2 (es) 2022-04-08
BR112021025416A2 (pt) 2022-02-22
AU2020295393A1 (en) 2022-01-06
JP2022537178A (ja) 2022-08-24
CA3143597A1 (en) 2020-12-24
WO2020257248A1 (en) 2020-12-24
US20220296657A1 (en) 2022-09-22
EP3983067A1 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
MX2021015711A (es) Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
MX2020009000A (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido.
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2022015243A (es) Antagonistas del receptor de lpa y usos de estos.
PH12021550872A1 (en) Therapeutic compounds
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2019003393A1 (es) Virus oncolíticos y método.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
MY193846A (en) Methods and compositions for treating hunter syndrome